Comments on:

FDA panel backs long-acting Boehringer inhaler

Back to the article » |
WASHINGTON (AP) — A panel of federal health experts on Tuesday overwhelmingly recommended approval for a long-acting inhaler to treat people suffering from chronic lung disease. The Food and Drug Administration panel voted 15-1, with one abstention, that Boehringer Ingelheim's once-daily Striverdi Respimat (STRIH-ver-dee Res-peh-mat) inhaler is safe and effective for chronic obstructive...

To learn more about commenting on and our community guidelines, please see our comments FAQ.